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Insulin-stimulated phosphorylation of protein
phosphatase 1 regulatory subunit 12B revealed
by HPLC-ESI-MS/MS
Kimberly Pham1†, Paul Langlais1†, Xiangmin Zhang1,2†, Alex Chao1, Morgan Zingsheim1 and Zhengping Yi1,2*

Abstract
Background: Protein phosphatase 1 (PP1) is one of the major phosphatases responsible for protein
dephosphorylation in eukaryotes. Protein phosphatase 1 regulatory subunit 12B (PPP1R12B), one of the regulatory
subunits of PP1, can bind to PP1cδ, one of the catalytic subunits of PP1, and modulate the specificity and activity of
PP1cδ against its substrates. Phosphorylation of PPP1R12B on threonine 646 by Rho kinase inhibits the activity of
the PP1c-PPP1R12B complex. However, it is not currently known whether PPP1R12B phosphorylation at threonine
646 and other sites is regulated by insulin. We set out to identify phosphorylation sites in PPP1R12B and to quantify
the effect of insulin on PPP1R12B phosphorylation by using high-performance liquid chromatography-electrospray
ionization-tandem mass spectrometry.
Results: 14 PPP1R12B phosphorylation sites were identified, 7 of which were previously unreported. Potential
kinases were predicted for these sites. Furthermore, relative quantification of PPP1R12B phosphorylation sites for
basal and insulin-treated samples was obtained by using peak area-based label-free mass spectrometry of fragment
ions. The results indicate that insulin stimulates the phosphorylation of PPP1R12B significantly at serine 29
(3.02 ± 0.94 fold), serine 504 (11.67 ± 3.33 fold), and serine 645/threonine 646 (2.34 ± 0.58 fold).
Conclusion: PPP1R12B was identified as a phosphatase subunit that undergoes insulin-stimulated phosphorylation,
suggesting that PPP1R12B might play a role in insulin signaling. This study also identified novel targets for future
investigation of the regulation of PPP1R12B not only in insulin signaling in cell models, animal models, and in
humans, but also in other signaling pathways.
Keywords: PPP1R12B, Phosphorylation, HPLC-ESI-MS/MS, Insulin signaling, Label-free, Quantification

Introduction
Protein phosphatase 1 (PP1) is one of the most abundant
serine/threonine phosphatases; it is responsible for most
protein dephosphorylation [1-3], which regulates diverse
biological processes in eukaryotes. Interactions between
catalytic subunits of PP1 (PP1c) and the regulatory subunits of PP1 (PP1R) lead to the formation of numerous
PP1 complexes that have unique substrate specificities,
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distinct subcellular localizations, and various regulatory
mechanisms [1-3].
Protein phosphatase 1 regulatory subunit 12B
(PPP1R12B), also known as myosin phosphatase target
subunit 2 (MYPT2), is one of the regulatory subunits of
PP1 and is predominantly expressed in cardiac/skeletal
muscle and brain [4,5]. PPP1R12B regulates muscle contraction, cardiac torsion, and sarcomere organization as
well as other cellular processes [5]. PPP1R12B contains
an RVxF binding motif (residues 53–56), several ankyrin
repeats, and a C-terminal leucine zipper domain, all of
which are involved in protein-protein interactions [4-7].
In addition, PPP1R12B has 108 serine, 63 threonine, and
16 tyrosine residues, 26 of which have been reported as
phosphorylated in the four large phosphorylation databases (www.phosphosite.org, phospho.elm.eu.org, www.

© 2012 Pham et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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uniprot.org, and www.phosida.com). However, only
phosphorylation at threonine 646 (Thr646) has been
shown to regulate PPP1R12B function [5]. Thr646 was
phosphorylated by Rho-kinase in kidney COS7 cells, reducing the activity of the PPP1R12B-PP1cδ complex [5].
Whether Thr646 phosphorylation plays the same inhibitory role in PPP1R12B-PP1cδ complex activity in other
cells remains to be determined.
Insulin is a potent anabolic hormone that modulates a
wide variety of biological processes. Protein phosphorylation plays a critical role in relaying the insulin signal
from initiation at the insulin receptor to the transport of
GLUT4 to the plasma membrane. Dysregulated protein
phosphorylation events in insulin signaling may contribute to various diseases, such as type 2 diabetes and cardiovascular diseases. Extensive research has been carried
out to study the role of kinases in insulin action. However, a mechanism for serine/threonine phosphatase action in insulin signal transduction is largely unknown. In
an effort to discover phosphatases that may be involved
in insulin signaling, we identified protein phosphatase 1
regulatory subunit 12A (PPP1R12A) as a novel endogenous, insulin stimulated interaction partner of insulin receptor substrate-1 (IRS-1), a well recognized player in
insulin signaling, implying that PPP1R12A might play a
role in IRS-1 dephosphorylation and insulin signaling
[8]. PPP1R12A is an isoform of PPP1R12B with high
expression in smooth muscle cells [9]. As mentioned
previously, PPP1R12B is predominantly expressed in cardiac/skeletal muscle and brain. Thus, it is possible that
PPP1R12B could anchor the catalytic subunit of PP1,
PP1cδ, to dephosphorylate IRS-1 in cardiac/skeletal
muscle and brain. More recently, we provided a relative
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global picture of PPP1R12A phosphorylation in CHO/IR
cells, and reported that insulin stimulated or suppressed
PPP1R12A phosphorylation at multiple sites [10]. It is
currently not known whether insulin plays a regulatory
role in PPP1R12B phosphorylation. Therefore, in the
present study, we used multi-segment high performance
liquid chromatography-electrospray ionization-tandem
mass spectrometry (HPLC-ESI-MS/MS) to identify and
quantify PPP1R12B phosphorylation sites that are regulated by insulin. We utilized the peak area of MS2 generated fragment ions, an approach developed in our
laboratory [11], to quantify relative changes in PPP1R12B
phosphorylation after insulin treatment.

Results
We hypothesized that insulin would regulate phosphorylation of PPP1R12B in Chinese hamster ovary cells
overexpressing human insulin receptor (CHO/IR).
Therefore we set out to identify PPP1R12B phosphorylation sites and assess how they respond to insulin. To
that end, overexpressed FLAG-tagged PPP1R12B was
isolated from CHO/IR cells by immunoprecipitation,
and then HPLC-ESI-MS/MS was performed, as
described in the Methods section. The spectra obtained
by HPLC-ESI-MS/MS confirmed the presence of
PPP1R12B with 63% sequence coverage (Figure 1).
Table 1 lists the PPP1R12B phosphopeptides detected by
HPLC-ESI-MS/MS and their respective predominant
phosphorylation sites. In all, 14 phosphorylation sites
were detected, 7 of which were previously not reported
as phosphorylation sites in the four large phosphorylation databases, and thus appear to be novel. These
novel, previously unknown phosphorylation sites include

Figure 1 Combined coverage map of peptides detected in tryptic digests of PPP1R12B expressed in CHO/IR cells using HPLC-ESI-MS/
MS analysis. 63% PPP1R12B sequence coverage was obtained from the 6 basal and 6 insulin samples as well as several preliminary experiments
for PPP1R12B peptide discovery. Detected peptides are highlighted in yellow; methionine oxidation sites are lowercase; serine/threonine
phosphorylation sites are highlighted in green; and novel phosphorylation sites are in boldface type.
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Table 1 PPP1R12B phosphopeptides and predicted potential kinases
Start

Stop

Peptide sequence

Phosphorylation site

Predicted kinases*

28

38

GpSLTEQEPAER

Ser29†

CK2α, CK2α’, DMPK, PAK-1, PAK-2, PAK-3, PAK-4, PKAα, PKAβ, p70-S6K

GSLpTEQEPAER

Thr31{

CK2α, CK2α’

Ser67

CK2α, CK2α’

54

76

VRFEDGAVFLAACpSSGDTDEVRK

445

458

pTGSHNMLSEVANSR

Thr445

DMPK, NEK2

501

511

KLNpSTSDIEEK

Ser504†

CK2α, CK2α’

KLNSTpSDIEEK

Ser506

CK2α, CK2α’

645

659

pSpTQGVTLTDLQEAER

Ser645/Thr646†

AIM1, PAK-1, PAK-2, PAK-3, PKAα, PKAβ, DMPK, Pim-2h/ DMPK, Pim-2h, RhoK

711

720

pSLDEEPICHR

Ser711

CK2α, CK2α’

755

773

FSVPDpSESSETTTNTTTAK

Ser760

CK2α, CK2α’

FSVPDSEpSSETTTNTTTAK

Ser762

CK2α, CK2α’, TLK1

837

853

LEpSGGSNPTTSDSYGDR

Ser839

ActRIIA, ActRIIB, CLK1, CLK2, DMPK, RAGE-1, TGFR-2

LESGGSNPTTpSDSYGDR

Ser847

CK2α, CK2α’

LESGGSNPTTSDpSYGDR

Ser849

ActRIIA, ActRIIB, TGFR-2

KMpSEMEEEMK

Ser947

CK2α, CK2α’

945

954

* Using NetworKIN 2.0 Beta (http://networkin.info/version_2_0/newPrediction.php) as well as literature searches.
†
Insulin-stimulated sites.
{
Novel phosphorylation sites are indicated in boldface type.
Kinase abbreviations: CK2α, casein kinase II, alpha chain; CK2α’, casein kinase II, alpha' chain; DMPK, myotonic dystrophy protein kinase; PAK-1, p21-activated
kinase 1; PAK-2, p21-activated kinase 2; PAK-3, p21-activated kinase 3; PAK-4, p21-activated kinase 4; PKAα, cAMP-dependent protein kinase, alpha-catalytic
subunit; PKAβ, cAMP-dependent protein kinase, beta-catalytic subunit; p70-S6K, ribosomal protein S6 kinase 1; NEK2, nimA-related protein kinase 2; AIM-1, Auroraand Ipl1-like midbody-associated protein 1; Pim-2h, serine/threonine-protein kinase Pim-2; RhoK, Rho kinase, TLK1, tousled-like kinase 1; ACTRIIA, activin receptor
type II precursor; ACTRIIB, activin receptor type IIB precursor; CLK1, CDC-like kinase 1; CLK2, CDC-like kinase 2; RAGE-1, renal tumor antigen 1; TGFR-2, TGF-beta
receptor type II precursor.

Thr31, Ser67, Ser711, Ser760, Ser762, Ser847, and
Ser849. Phosphorylation of PPP1R12B at Thr646,
observed in kidney cells by Okamoto et al. [5], was confirmed in CHO/IR cells; however, based on the tandem
mass spectra, the peptide containing phosphorylated
Thr646 might also be phosphorylated at Ser645 [12,13].
We confirmed the phosphorylation of PPP1R12B at
Ser29 [14], Ser445 [14], Ser504 [14], Ser506 [15], Ser839
[14,16], and Ser947 [14,17]. The MS/MS spectra for the
peptides containing phosphorylated Ser645/Thr646 and
Ser760 are shown in Additional file 1: Figure S1 and
Figure S2. We have posted the Scaffold file on http://
cphs-web.cphs.wayne.edu/zyi/PPP1R12B so that readers
can access all MS/MS spectra after installation of the
Scaffold viewer, which is freely available on http://www.
proteomesoftware.com.
To assess the effect of insulin on PPP1R12B phosphorylation, serum-starved, CHO/IR cells overexpressing
FLAG-tagged PPP1R12B were either left untreated or
treated with insulin. FLAG-tagged PPP1R12B was
immunoprecipitated and resolved by 10% SDS-PAGE.
Coomassie blue stain was used to visualize the protein
(Additional file 1: Figure S3), after which the gel area
corresponding to PPP1R12B was excised and subjected
to trypsin digestion. Relative quantification of phosphorylation by HPLC-ESI-MS/MS was performed as
described in the Methods section. Six independent biological replicates (6 control and 6 insulin-treated, total

12 samples) were utilized to increase the confidence of
our findings. The control and insulin-stimulated samples
that were harvested on the same day, resolved on the
same gel, and analyzed by HPLC-ESI-MS/MS during the
same period of time were paired to minimize day-to-day
variations. Eight nonphosphorylated PPP1R12B peptides
were used as endogenous internal standards to measure
total PPP1R12B present per sample (Table 2) and their
peak area and retention times are listed in Additional file
2: Table S1.
Analysis of PPP1R12B phosphorylation revealed that
several PPP1R12B phosphopeptides contain multiple
phosphorylation sites (Table 1). To quantify the phosphorylated peptides, we generated MS2 fragment ions
and used the peak areas of the fragment b and y ions
(Table 3), as described by Langlais et al. [11]. Among
the 14 phosphorylation sites identified, we obtained
quantitative information for 6 of them (Figure 2 and
Table 4). Please note that even though we performed 6
independent comparisons between basal and insulin
treated conditions, 2 of the comparisons had a relatively
larger deviation from the other 4 comparisons. Therefore, they were excluded from Figure 2 and Table 4.
Nonetheless, biological findings regarding insulin stimulation for 6 comparisons are the same as those for 4
comparisons. Each PPP1R12B phosphorylation site was
normalized by the average value of the respective control
sample and then expressed as fold change over control
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Table 2 PPP1R12B internal standard peptides
Start

Stop

Peptide sequence

Molecular weight (Da)

Quantified (m/z)*

282

303

LGQTPFDVADEGLVEHLELLQK

2451.2766

817.7637 (+3)

327

333

IQSGFFK

826.4458

397

417

SSITEQIPAPAQNTFSASSAR

2163.0677

492

500

SYISSLAPR

993.5364

515

522

ESAVNLVR

887.4945

741

754

PSLYTSSHLLWTNR

1674.8598

837

853

LESGGSNPTTSDSYGDR

1742.7464

966

975

LKDENGALIR

1128.6371

1226.1419 (+2)
413.7265 (+2)
826.4458 (+1)
721.6941 (+3)
1082.0375 (+2)
497.2718 (+2)
993.5364 (+1)
444.2509 (+2)
887.4945 (+1)
558.9581 (+3)
837.9336 (+2)
871.8768 (+2)
564.8222 (+2)
1128.6371 (+1)
*
m/z, mass-to-charge ratio.
Combined peak areas for the +1, +2, and +3 (when detected) charge states for each peptide were obtained by integration of the appropriate reconstructed ion
chromatograms.

Table 3 Unique fragment ions used to quantify phosphorylation sites
Start

Stop

Peptide sequence

Phosphorylation site

28

38

GpSLTEQEPAER

Ser29

501

645

711

755

837

*

511

659

720

773

853

KLNpSTSDIEEK

pSpTQGVTLTDLQEAER

pSLDEEPICHR

FSVPDpSESSETTTNTTTAK

LEpSGGSNPTTSDSYGDR

Ser504

Ser645/Thr646

Ser711

Ser760†

Ser839

Product ion (m/z)*

Mass (Da)

y8 (+1)

959.40

y9 (+1)

1072.50

b4 (+1)

523.23

y7 (+1)

821.39

b2 (+1)

269.05

b3 (+1)

397.11

b4 (+1)

454.13

b5 (+1)

553.20

y10 (+1)

1175.59

y11 (+1)

1274.66

y12 (+1)

1331.68

y13 (+1)

1459.74

y6 (+1)

754.37

y7 (+1)

883.41

y8 (+1)

998.44

b7 (+1)

842.30

y12 (+1)

1241.59

y13 (+1)

1370.63

b3 (+1)

410.10

y12 (+1)

1299.50

y13 (+1)

1356.60

y14 (+1)

1413.60

m/z, mass-to-charge ratio.
†
Since Scaffold PTM analysis indicated that only Ser760 or Ser762 is phosphorylated on this peptide, unique fragment ion selection was based on the comparison
between pSer760 and pSer762.
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Figure 2 The effect of insulin on PPP1R12B phosphorylation. Immunoprecipitated FLAG-tagged PPP1R12B was resolved by 10% SDS-PAGE
and stained with Coomassie blue to visualize the protein. The gel area corresponding to PPP1R12B was excised and subjected to trypsin
digestion and HPLC-ESI-MS/MS analysis as described in the Methods section. Relative quantification of each phosphopeptide was obtained by
comparing normalized peak-area ratios against the average of 8 representative PPP1R12B peptides. Each PPP1R12B phosphorylation site was
normalized by the average value of the respective basal sample and then expressed as fold change over control (n = 4). Box and whisker plots of
the ratios were utilized to visualize the effect of insulin on PPP1R12B phosphorylation.

± SEM (n = 4). Phosphorylation of PPP1R12B at Ser711,
Ser760, and Ser839 was not significantly affected by insulin (Figure 2 and Table 4). In contrast, significant insulin stimulation was observed for the phosphorylation of
PPP1R12B at Ser29, Ser504, and Ser645/Thr646 (Figure 2
and Table 4). Unfortunately, we were unable to discern
between the isobaric peptides of aa645-659 that are
phosphorylated at either Ser645 or Thr646, as the respective y14 and y15 ions were not readily detectable
(which explains why thus were not included in Table 3).
We have been forced to group the quantification of
these 2 phosphorylation sites together. After correcting
for sample loading by dividing the peak area for each
phosphopeptide by the corresponding mean peak area of
PPP1R12B representative peptides from each sample,
these three sites showed an increase in all 4 comparisons
after insulin treatment (P < 0.05). Phosphorylation
increased 3.02 ± 0.94 fold at Ser29, 11.67 ± 3.33 fold at
Ser504, and 2.34 ± 0.58 fold at Ser645/Thr646. The
increased phosphorylation of PPP1R12B after insulin
stimulation has not been previously reported for these
sites. We performed a literature search and also utilized
NetworKIN 2.0, an online bioinformatics tool, to predict
kinases capable of phosphorylating PPP1R12B (Table 1)
[18,19]. The potential kinases for the PPP1R12B

phosphorylation sites that underwent insulin stimulation
(i.e., Ser29, Ser504, and S695/Thr646) included p21activated kinases (PAKs), casein kinase II (CK2), myotonic dystrophy protein kinase (DMPK), and Rho kinase,
all of which have been shown to be activated by insulin
[20-22]. Future studies will test the involvement of these
kinases in insulin-stimulated phosphorylation of PPP1R12B.

Discussion
It has been shown that phosphorylation of PPP1R12B at
Thr646 by Rho kinase reduces the activity of the
PPP1R12B-PP1cδ complex against smooth muscle myosin light chain in COS7 kidney cells [5]. Whether
Thr646 phosphorylation plays the same inhibitory role
in PPP1R12B-PP1cδ complex activity in CHO/IR cells
remains to be elucidated. A previous report indicated
that insulin might stimulate Rho kinase activity [23].
Thus, it is possible that after insulin stimulation, Rho
kinase phosphorylates Thr646 in PPP1R12B in CHO/IR
cells and serves as a negative regulator of the PPP1R12BPP1cδ complex. We also observed the phosphorylation of
PPP1R12B at the pThr646 proximal site, Ser645, although
these 2 phospho sites were not distinguishable based on
the MS/MS spectrum, and whether they behave similarly
in the regulation of PPP1R12B is unclear at present.
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Table 4 Effect of insulin on PPP1R12B phosphorylation,
n=4

Table 4 Effect of insulin on PPP1R12B phosphorylation,
n = 4 (Continued)

Ser29

Average

3.44E-05

SEM
Experiment

Ratio †

Normalized peak area #

1.00

0.72

0.06

0.06

Ser839
Ratio †

Normalized peak area #

Control

Insulin

Control

Insulin

1

1.10E-05

3.89E-05

0.43

1.51

Basal

Insulin

Basal

Insulin

2

1.20E-05

6.84E-05

0.46

2.65

1

1.36E-05

1.67E-05

0.16

0.20

3

2.85E-05

5.64E-05

1.10

2.18

2

2.74E-05

5.48E-05

0.33

0.66

4

5.18E-05

1.48E-04

2.01

5.75

3

3.23E-05

0.00E + 00

0.39

0.00

Average

2.58E-05

1.00

3.02*

4

2.61E-04

2.70E-04

0.37

0.94

Average

8.36E-05

SEM

Experiment

Ser504
Experiment

SEM
Ratio †

Normalized peak area #
Insulin

Control

1

2.12E-06

7.66E-05

0.22

8.06

2

2.53E-05

1.85E-04

2.66

19.45

3

1.06E-05

1.39E-04

1.11

14.62

4

0.00E + 00

4.33E-05

0.00

4.56

Average

9.51E-06

1.00

11.67*

0.60

3.33

Insulin

Ser645/T646
Experiment

Ratio †

Normalized peak area #
Control

Insulin

Control

Insulin

1

1.50E-04

3.00E-04

0.52

1.05

2

2.93E-04

5.89E-04

1.02

2.05

3

3.01E-04

7.03E-04

1.05

2.45

4

4.04E-04

1.10E-03

1.41

3.82

Average

2.87E-04

1.00

2.34*

0.18

0.58

SEM
Ser711
Experiment

Ratio †

Normalized peak area #
Basal

Insulin

Basal

Insulin

1

4.15E-05

4.29E-05

0.56

0.58

2

5.58E-05

2.36E-05

0.76

0.32

3

7.55E-05

8.23E-05

1.02

1.12

4

1.22E-04

6.52E-05

1.66

0.88

Average

7.37E-05

SEM

1.00

0.73

0.24

0.17

Ser760
Experiment

Ratio †

Normalized peak area #

3.24
1.02

0.71

0.75

#

Control

SEM

3.12
1.00

Basal

Insulin

Basal

Insulin

1

3.43E-05

2.13E-05

1.00

0.62

2

3.59E-05

2.85E-05

1.04

0.83

3

2.84E-05

2.83E-05

0.83

0.82

4

3.89E-05

2.08E-05

1.13

0.60

Normalized peak area: obtained by dividing the peak area of a
phosphopeptide by the mean value of the peak area of the 8
unphosphorylated representative peptides of PPP1R12B.
†
Ratio: obtained by dividing the normalized peak area for a phosphopeptide
in each experiment by the average of the normalized peak area under the
control condition.
* P < 0.05 compared with control.

Mutation of Thr646 or Ser645 to alanine is on-going to
assess the role of PPP1R12B phosphorylation on PP1c activity and insulin signaling.
Ser29 and Thr31 are in close proximity to the PP1c
binding motif (K/R-I/V-X-F/W, residues 53–56 in
human PPP1R12B) [5]. In addition, the crystalline
structure of the PP1 complex between the chicken
PP1c δ isoform (also called β isoform) and amino acids
1–299 of protein phosphatase 1 regulatory subunit
12A (PPP1R12A) (also called MYPT1, an isoform of
PPP1R12B) has been resolved [24]. It indicates that
residues 1–34, which precede the PP1c binding motif
in human PPP1R12A (residues 35–38), also interact
with PP1cδ. It has been shown that a short peptide
(residues 23–38) of PPP1R12A, which contains the
PP1c binding motif but lacks the N terminus, binds to
PP1c but has no effect on PP1cδ catalytic activity [25],
whereas a peptide containing residues 1–38 of
PPP1R12A both interacts with PP1c and increases its
phosphatase activity. Hence, it is reasonable to conclude that some structure within residues 1–22 is responsible for the increased catalytic activity. To date,
structural information for PPP1R12B is lacking. However, based on the similarity between PPP1R12A and
PPP1R12B as well as the insulin-stimulated phosphorylation of Ser29 (pS29), we speculate that pS29 might
play a role in regulating PP1cδ activity when it is in a
complex with PPP1R12B. Without pS29, PPP1R12B
might still bind to PP1cδ through the PP1c binding
motif; however, the resulting complex might not have
the full phosphatase activity against its substrates. We
are in the process of mutating Ser29 to alanine to test

Pham et al. Proteome Science 2012, 10:52
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the functional consequence of this mutation, such as
effect on phosphatase activity.
Ser504 of PPP1R12B exhibited over 11-fold more
phosphorylation after insulin treatment. Because it was
found, by surface plasmon resonance, that PP1cδ might
interact with the PPP1R12A truncation containing residues 304–511 [25], we speculate that phosphorylation at
Ser504 might also be involved in the interplay between
PPP1R12B and PP1cδ. The increase in phosphorylation
of PPP1R12B at Ser504 represents the strongest fold
change of any insulin-stimulated serine or threonine
phosphorylation site that we have studied to date using
this mass spectrometry technique to quantify protein
phosphorylation [11,26-28]. The strength of the insulinstimulated PPP1R12B phosphorylation at Ser504 could
indicate that it is a major regulatory mechanism responsible for controlling PPP1R12B function in insulin signaling. Mutation of Ser504 to alanine is on-going to
assess the function of this phosphorylation site in regulating PPP1R12B and PP1c activity.
Insulin signaling is crucial to many biological processes,
such as glycogen synthesis, glucose transport, mitogenesis,
and protein synthesis. The intracellular actions of insulin
are mediated by controlled protein phosphorylation and
dephosphorylation [29]. Insulin activates the insulin receptor, and the activated insulin receptor then phosphorylates
tyrosine residues IRS-1, which allows IRS-1 to recruit phosphatidylinositide 3-kinase and leads to phosphorylation of
Akt on threonine/serine residues. Activated Akt phosphorylates its substrate proteins, such as AS160, and promotes
GLUT4 translocation to the plasma membrane, leading to
enhanced glucose uptake. In addition, activated Akt can increase glycogen synthesis by phosphorylating glycogen synthase kinase 3, and decreasing the phosphorylation of
glycogen synthase. Moreover, phosphorylated Akt enhances
protein synthesis through serine/threonine phosphorylation
of mammalian target of rapamycin and ribosomal protein
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S6 kinase beta-1 [29]. Furthermore, IRS-1 interacts with
growth factor receptor binding protein 2, leading to serine/
threonine phosphorylation of a number of signaling proteins in the mitogen-activated protein kinase pathway and
subsequent promotion of cell survival and mitogenesis [30].
As discussed above, several of the serine/threonine kinases,
such as Akt, mammalian target of rapamycin, ribosomal
protein S6 kinase beta-1, glycogen synthase kinase 3, and
mitogen-activated protein kinase, have been shown to play
a role in insulin signaling. However, a mechanism for
serine/threonine phosphatase action in insulin signal transduction is not known. The present study identified
PPP1R12B, a regulatory subunit of PP1 (which is a serine/
threonine protein phosphatase), as a new insulin-signaling
protein with site-specific phosphorylation that is regulated
by insulin in CHO/IR cells. The results presented in this
study will provide targets for future investigations delineating the role of serine/threonine phosphatases in insulin
signaling.

Conclusions
We analyzed the effect of insulin on PPP1R12B phosphorylation using HPLC-ESI-MS/MS and found that insulin stimulated phosphorylation of Ser29, Ser504, and
Ser645/Thr646. We also identified 7 previously unreported PPP1R12B phosphorylation sites, namely, Thr31,
Ser67, Ser711, Ser760, Ser762, Ser847, and Ser849. Although these novel sites did not respond to insulin in
CHO/IR cells, they provide targets for investigating the
regulation of PPP1R12B and/or PP1cδ in other cells, such
as smooth muscle cells, cardiomyocytes, or COS7 kidney
cells. A summary of the PPP1R12B phosphorylation findings is provided in Figure 3. It is noted that overexpression
of insulin receptor might lead to artifactual phosphorylation. Nonetheless, these results provide novel targets for
future investigation of the regulation of PPP1R12B not
only in insulin signaling in cell models, animal

Figure 3 Summary of PPP1R12B phosphorylation findings. The black bar preceding the Ankyrin repeats represents the PP1c binding motif,
amino acids 53–56. An asterisk (*) indicates sites with a significant increase in phosphorylation after insulin stimulation. Novel sites are indicated
in boldface type.
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models, and in humans, but also in other signaling pathways. Future experiments will confirm the effect of insulin
on PPP1R12B phosphorylation in both animal and human
muscle, while site-specific mutagenesis will be employed to
assess the role of PPP1R12B phosphorylation on PP1c activity and insulin signaling within in vitro insulin-signaling
models, such as L6 myotubes.

Page 8 of 9

with 10 ppm error tolerance for precursor-ion masses
acquired using FTICR and 0.5 Dalton for the fragment
ions acquired using the LTQ mass analyzer. Relative
quantification of each phosphopeptide was obtained by
comparing normalized peak-area ratios for control and
insulin-treated samples [11,26,32].
Statistical analysis

Methods
Materials

The sequencing-grade trypsin and anti-FLAG antibody
were purchased from Sigma (St. Louis, MO), and the
C18 ZipTip from Millipore (Billerica, MA). Chinese
hamster ovary cells overexpressing the insulin receptor
(CHO/IR) were a gift from Dr. Feng Liu (University of
Texas Health Science Center at San Antonio, TX). Establishment of the CHO/IR cell line was described previously [31]. The cDNA encoding full-length wild-type
human PPP1R12B was a gift from Dr. Ryuji Okamoto
and Dr. Masaaki Ito (Mie University, Tsu, Mie, Japan).
Cell culture, transfection, immunoprecipitation, and
SDS-PAGE

CHO/IR cells were transfected with 5–10 μg of FLAGtagged PPP1R12B plasmid DNA using Lipofectamine reagent (Invitrogen, Carlsbad, CA), serum starved for 4 h
at 37°C, and left untreated or treated with insulin (100
nM) for 15 min at 37°C. The cells were lysed, and cell
lysates (1 mg) were diluted in lysis buffer and incubated
with 2 μg of anti-FLAG antibody for PPP1R12B purification. The immunoprecipitates were collected with Protein A agarose beads (Sigma, St. Louis, MO). Samples
were boiled in sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer and
resolved by 10% 1D-SDS-PAGE. The proteins were then
visualized by Coomassie blue staining (Sigma, St. Louis,
MO). Please see Additional file 3 for more details.
In-gel digestion and mass spectrometry

In-gel digestion and mass spectrometry were performed
as described previously [11,26,32]. Briefly, the gel portions containing PPP1R12B were excised, destained,
dehydrated, dried, and subjected to trypsin digestion
overnight. The resulting peptides were desalted and analyzed by on-line HPLC on a linear trap quadrupoleFourier transform ion cyclotron resonance (LTQFTICR). Please see the Additional file 3 for details.
Phosphorylation sites were located using Scaffold
PTM (version 1.0.3, Proteome Software, Portland, OR), a
program based on the Ascore algorithm [33,34]. Sites
with Ascores ≥ 13 (P ≤ 0.05) were considered confidently
localized [33,34].
Peak areas for each peptide were obtained by integrating the appropriate reconstructed ion chromatograms

Statistical significance was assessed by comparing control and insulin-stimulated phosphopeptide peak areas
(normalized to PPP1R12B representative peptides as
described above) using the paired t-test.

Additional files
Additional file 1: Figure S1. Tandem mass spectrum of Ser645/Thr646
(ambiguous) phosphorylation in PPP1R12B tryptic phosphopeptide
645-659, pSpTQGVTLTDLQEAER, as well as the theoretical and
experimental m/z values for detected fragment ions. *Loss of H3PO4 (98
units) from the indicated fragment. #Loss of H2O (18 units). The ions
corresponding to b4, b5, y10, y11, and y12 are consistent with
phosphorylation on Ser645/Thr646. Figure S2. Tandem mass spectrum of
Ser760 phosphorylation in PPP1R12B tryptic phosphopeptide 755-773,
FSVPDpSESSETTTNTTTAK as well as the theoretical and experimental m/z
values for detected fragment ions. *Loss of H3PO4 (98 units) from the
indicated fragment. #Loss of H2O (18 units). The ions corresponding to
b5, b6, y11, y12, and y13 are consistent with phosphorylation on Ser760.
Figure S3. The representative image of the stained gel from which the
bands were excised.
Additionalf file 2: Table S1. PPP1R12B representative
unphosphorylated peptides peak area and retention time.
Additional file 3: Supplemental materials and methods.
Abbreviations
CHO/IR: Chinese hamster ovary cells overexpressing human insulin receptor;
HPLC-ESI-MS: High-performance liquid chromatography-electrospray
ionization-mass spectrometry; IRS-1: Insulin receptor substrate-1; LTQFTICR: Linear trap quadrupole-Fourier transform ion cyclotron resonance; MS/
MS: Tandem mass spectrometry; PP1c: Protein phosphatase 1 catalytic
subunit; PPP1R12B: Protein phosphatase 1 regulatory subunit 12B.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KP carried out the experiments, analyzed the data, and wrote the
manuscript; PL organized and analyzed the data, and wrote and revised the
manuscript; XZ wrote and revised the manuscript; AC analyzed the data; MZ
carried out the experiments; ZY conceived and designed the experiments,
analyzed the data, wrote and revised the manuscript. All authors approved
the final version of the article.
Acknowledgements
This research was supported by funds from the National Institutes of Health
R01DK081750 (ZY) and an American Diabetes Association Clinical/
Translational Research Award 7-09-CT-56 (ZY) as well as the Howard Hughes
Medical Institute through the Undergraduate Science Education Program
and from the Arizona State University School of Life Sciences (KP).
Received: 13 February 2012 Accepted: 31 July 2012
Published: 1 September 2012
References
1. Bollen M, Peti W, Ragusa MJ, Beullens M: The extended PP1 toolkit:
designed to create specificity. Trends Biochem Sci 2010, 35:450–458.

Pham et al. Proteome Science 2012, 10:52
http://www.proteomesci.com/content/10/1/52

2.
3.
4.

5.

6.
7.

8.

9.
10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

Cohen PT: Protein phosphatase 1-targeted in many directions. J Cell Sci
2002, 115:241–256.
Virshup DM, Shenolikar S: From promiscuity to precision: protein
phosphatases get a makeover. Mol Cell 2009, 33:537–545.
Grassie ME, Moffat LD, Walsh MP, Macdonald JA: The myosin phosphatase
targeting protein (MYPT) family: a regulated mechanism for achieving
substrate specificity of the catalytic subunit of protein phosphatase type
1δ. Arch Biochem Biophys 2011, 510:147–159.
Okamoto R, Kato T, Mizoguchi A, Takahashi N, Nakakuki T, Mizutani H, Isaka
N, Imanaka-Yoshida K, Kaibuchi K, Lu Z, et al: Characterization and function
of MYPT2, a target subunit of myosin phosphatase in heart. Cell Signal
2006, 18:1408–1416.
Ito M, Nakano T, Erdodi F, Hartshorne DJ: Myosin phosphatase: structure,
regulation and function. Mol Cell Biochem 2004, 259:197–209.
Shichi D, Arimura T, Ishikawa T, Kimura A: Heart-specific small subunit of
myosin light chain phosphatase activates rho-associated kinase and
regulates phosphorylation of myosin phosphatase target subunit 1. J Biol
Chem 2010, 285:33680–33690.
Geetha T, Langlais P, Luo M, Mapes R, Lefort N, Chen SC, Mandarino LJ, Yi Z:
Label-free proteomic identification of endogenous, insulin-stimulated
interaction partners of insulin receptor substrate-1. J Am Soc Mass
Spectrom 2011, 22:457–466.
Matsumura F, Hartshorne DJ: Myosin phosphatase target subunit: Many
roles in cell function. Biochem Biophys Res Commun 2008, 369:149–156.
Chao A, Xiangmin Z, Danjun M, Langlais P, Moulun-Luo LJM, Zingsheim M,
Pham K, Dillon J, Zhengping Y: Site-Specific Phosphorylation of Protein
Phosphatase 1 Regulatory Subunit 12A Stimulated or Suppressed by
Insulin. Journal of Proteomics 2012, 75:3342–3350.
Langlais P, Mandarino LJ, Yi Z: Label-free relative quantification of coeluting isobaric phosphopeptides of insulin receptor substrate-1 by
HPLC-ESI-MS/MS. J Am Soc Mass Spectrom 2010, 21:1490–1499.
Moritz A, Li Y, Guo A, Villen J, Wang Y, MacNeill J, Kornhauser J, Sprott K,
Zhou J, Possemato A, et al: Akt-RSK-S6 kinase signaling networks
activated by oncogenic receptor tyrosine kinases. Sci Signal 2010, 3:ra64.
Pan C, Gnad F, Olsen JV, Mann M: Quantitative phosphoproteome analysis
of a mouse liver cell line reveals specificity of phosphatase inhibitors.
Proteomics 2008, 8:4534–4546.
Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen
J, Haas W, Sowa ME, Gygi SP: A tissue-specific atlas of mouse protein
phosphorylation and expression. Cell 2010, 143:1174–1189.
Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA: Quantitative
phosphoproteomics of vasopressin-sensitive renal cells: regulation of
aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci U S A 2006,
103:7159–7164.
Zanivan S, Gnad F, Wickstrom SA, Geiger T, Macek B, Cox J, Fassler R, Mann
M: Solid tumor proteome and phosphoproteome analysis by high
resolution mass spectrometry. J Proteome Res 2008, 7:5314–5326.
Imami K, Sugiyama N, Kyono Y, Tomita M, Ishihama Y: Automated
phosphoproteome analysis for cultured cancer cells by two-dimensional
nanoLC-MS using a calcined titania/C18 biphasic column. Anal Sci 2008,
24:161–166.
Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jorgensen C, Miron IM,
Diella F, Colwill K, Taylor L, Elder K, et al: Systematic discovery of in vivo
phosphorylation networks. Cell 2007, 129:1415–1426.
Linding R, Jensen LJ, Pasculescu A, Olhovsky M, Colwill K, Bork P, Yaffe MB,
Pawson T: NetworKIN: a resource for exploring cellular phosphorylation
networks. Nucleic Acids Res 2008, 36:D695–699.
Sun J, Khalid S, Rozakis-Adcock M, Fantus IG, Jin T: P-21-activated protein
kinase-1 functions as a linker between insulin and Wnt signaling
pathways in the intestine. Oncogene 2009, 28:3132–3144.
Tanasijevic MJ, Myers MG Jr, Thoma RS, Crimmins DL, White MF, Sacks DB:
Phosphorylation of the insulin receptor substrate IRS-1 by casein kinase
II. J Biol Chem 1993, 268:18157–18166.
Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, Kondo R,
Reddy S, Dillmann WH, Palacin M, et al: Role of myotonic dystrophy
protein kinase (DMPK) in glucose homeostasis and muscle insulin action.
PLoS One 2007, 2:e1134.
Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH,
Kaibuchi K, Kahn BB, Masuzaki H, et al: Role of Rho-kinase in regulation of
insulin action and glucose homeostasis. Cell metabolism 2005, 2:119–129.

Page 9 of 9

24. Terrak M, Kerff F, Langsetmo K, Tao T, Dominguez R: Structural basis of
protein phosphatase 1 regulation. Nature 2004, 429:780–784.
25. Toth A, Kiss E, Herberg FW, Gergely P, Hartshorne DJ, Erdodi F: Study of the
subunit interactions in myosin phosphatase by surface plasmon
resonance. Eur J Biochem 2000, 267:1687–1697.
26. Yi Z, Langlais P, De Filippis EA, Luo M, Flynn CR, Schroeder S, Weintraub ST,
Mapes R, Mandarino LJ: Global assessment of regulation of
phosphorylation of insulin receptor substrate-1 by insulin in vivo in
human muscle. Diabetes 2007, 56:1508–1516.
27. Langlais P, Yi Z, Mandarino LJ: The Identification of Raptor as a Substrate
for p44/42 MAPK. Endocrinology 2011, 152:1264–1273.
28. Højlund K, Yi Z, Lefort N, Langlais P, Bowen B, Levin K, Beck-Nielsen H,
Mandarino L: Human ATP synthase beta is phosphorylated at multiple
sites and shows abnormal phosphorylation at specific sites in insulinresistant muscle. Diabetologia 2010, 53:541–551.
29. Siddle K: Signalling by insulin and IGF receptors: supporting acts and
new players. J Mol Endocrinol 2011, 47:R1–10.
30. Yamashiro S, Yamakita Y, Totsukawa G, Goto H, Kaibuchi K, Ito M,
Hartshorne DJ, Matsumura F: Myosin phosphatase-targeting subunit 1
regulates mitosis by antagonizing polo-like kinase 1. Developmental cell
2008, 14:787–797.
31. Ando A, Momomura K, Tobe K, Yamamoto-Honda R, Sakura H, Tamori Y,
Kaburagi Y, Koshio O, Akanuma Y, Yazaki Y, et al: Enhanced insulin-induced
mitogenesis and mitogen-activated protein kinase activities in mutant
insulin receptors with substitution of two COOH-terminal tyrosine
autophosphorylation sites by phenylalanine. J Biol Chem 1992,
267:12788–12796.
32. Yi Z, Luo M, Mandarino LJ, Reyna SM, Carroll CA, Weintraub ST:
Quantification of phosphorylation of insulin receptor substrate-1 by
HPLC-ESI-MS/MS. J Am Soc Mass Spectrom 2006, 17:562–567.
33. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based
approach for high-throughput protein phosphorylation analysis and site
localization. Nat Biotechnol 2006, 24:1285–1292.
34. Zhai B, Villen J, Beausoleil SA, Mintseris J, Gygi SP: Phosphoproteome
analysis of Drosophila melanogaster embryos. J Proteome Res 2008,
7:1675–1682.
doi:10.1186/1477-5956-10-52
Cite this article as: Pham et al.: Insulin-stimulated phosphorylation of
protein phosphatase 1 regulatory subunit 12B revealed by HPLC-ESIMS/MS. Proteome Science 2012 10:52.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

